Airflow relieves chronic breathlessness in people with advanced disease: an exploratory systematic review and meta-analyses.

Flavia Swan, Wolfson Palliative Care Research Centre, Institute for Clinical and Applied Health Research, Allam Medical Building, Hull York Medical School (HYMS), University of Hull, Cottingham Rd, Hull, HU6 7RX

Alison Newey, Community Palliative Care, University Hospital of South Manchester NHS Foundation Trust, Withington Community Hospital, Nell Lane, Manchester, M20 2LR

Martin Bland, Department of Health Sciences, Seebohm Rowntree Building, University of York, Heslington, York YO10 5DD

Victoria Allgar, Department of Health sciences, University of York, Heslington, York YO10 5DD

Sara Booth, Associate Lecturer, Department of Oncology, University of Cambridge, Cambridge CB2 0QQ

Claudia Bausewein, Department of Palliative Medicine, Munich University Hospital, Marchioninistr. 15, 81377 München, Germany

Janelle Yorke, School of Health Sciences, Division Nursing, Midwifery and Social Work, University of Manchester. Room 5.320, Jean McFarlane University, University Place, Oxford Road, Manchester M13 9PL and Christie Patient Centred Research group (CPCR) The Christie NHS Foundation Trust, Manchester.

Miriam Johnson, Wolfson Palliative Care Research Centre, Institute for Clinical and Applied Health Research, Allam Medical Building, Hull York Medical School (HYMS), University of Hull, Cottingham Rd, Hull, HU6 7RX
Abstract

Background: Chronic breathlessness is a neglected symptom of advanced diseases.
Aim: To examine the effect of airflow for chronic breathlessness relief.
Design: Exploratory systematic review and meta-analysis.
Data sources: Medline, CINAHL, AMED and Cochrane databases were searched (1985 – 2018) for observational studies or randomised controlled trials of airflow as intervention or comparator. Selection against pre-defined inclusion criteria, quality-appraisal and data extraction were conducted by two independent reviewers with access to a third for unresolved differences. “Before and after” breathlessness measures from airflow arms were analysed. Meta-analysis was carried out where possible.
Results: 16/78 studies (n=929) were included; 11 randomised controlled trials of oxygen vs medical air, four randomised controlled trials and one fan cohort study. Three meta-analyses were possible: i) Fan at rest in three studies (n=111) offered significant benefit for breathlessness intensity (0-100mm Visual Analogue Scale and 0- 10 Numerical Rating Scale), mean difference -11.17 (95% confidence intervals -16.60 to -5.74), p=0.06 I² 64%. ii) Medical air via nasal cannulae at rest in two studies (n=89) improved breathlessness intensity (visual analogue scale), mean difference -12.0mm, 95% confidence intervals -7.4 to -16.6, P<0.0001 I² =0%. iii) Medical airflow during a constant load exercise test before and after rehabilitation (n=29) in two studies improved breathlessness intensity (mBorg, 0-10) mean difference -2.9, 95% confidence intervals -3.2 to -2.7, p<0.0001 I² =0%.
Conclusion: Airflow appears to offer meaningful relief of chronic breathlessness and should be considered as an adjunct treatment in the management of breathlessness.

Keywords:

- dyspnea,
- self-management,
- review,
- airflow (relevant term as the intervention subject heading)
What is already known?

- Randomised controlled trials and cohort data have demonstrated that airflow delivered from the fan at rest offers significant relief of breathlessness.
- Systematic review and randomised controlled trials of oxygen vs medical air have failed to demonstrate additional benefit from oxygen therapy and suggest that medical air delivery, airflow, is likely to be an active intervention.
- All current evidence available for the effect of airflow for chronic breathlessness relief has not been explored using systematic review methods.

What this paper adds

This exploratory systematic review and meta-analyses provide promising data to suggest that:

- airflow from the fan at rest improves breathlessness in people with breathlessness due to a variety of causes
- airflow delivered as cylinder medical air at rest improves breathlessness in advanced cancer
- airflow delivered as cylinder medical air during a constant load exercise test in people with chronic obstructive pulmonary disease and who have completed pulmonary rehabilitation

Implications for practice and theory

- Clinicians should consider the fan as an adjunct to treatment for breathlessness at rest in patients who do not require oxygen-enriched air.
- Airflow may benefit exertion-induced breathlessness, but further work is required to investigate the role of the fan with everyday general activity and in relation to exercise.
- Recovery time from exertion-induced breathlessness, self-efficacy and daily activity are key outcomes to explore in future studies of airflow.
Introduction

Breathlessness is a common, often poorly managed symptom in people with advanced diseases. It is associated with reduced quality of life (1), decreased activities of daily living (2), unplanned emergency hospital attendance and admission. (3-5) Breathlessness inflicts devastating and disabling physical, psychological and social burden on normal daily life for the patient, carers and close family members (6-8). Chronic breathlessness, that is, breathlessness that persists despite optimal treatment for the underlying pathophysiology and causing such disability (9), all too often is left for patients to manage themselves despite a developing evidence base for interventions targeted at the breathlessness itself.

Growing evidence supports complex non-pharmacological interventions to reduce the impact of the symptom and improve quality of life. (10-12) Components target peripheral and central afferent sources of breathlessness sensation, such as facial airflow delivered by the battery-operated hand-held fan (fan). (13-17) Cooling of the facial skin innervated by the 2nd and 3rd branches of the trigeminal nerve, nasal mucosae or the upper airway flow receptors could modulate the central perception of breathlessness leading to decreased neural respiratory drive, thereby reducing the sensation of breathlessness. (18-22) A recent multi-methods secondary analysis of qualitative interview data from three studies found that 80/111 (72%) participants experienced benefit when the fan was used in conjunction with other components of a complex intervention. (23) Airflow delivered from the fan may offer a valuable contribution to the self-management of chronic breathlessness (13, 15, 23), and has been identified as a potentially useful strategy in a variety of situations, e.g. breathlessness crisis (24), a component of pulmonary rehabilitation to assist recovery from exercise, or with general everyday activities. (15)

Systematic reviews of oxygen in a variety of non-hypoxic patient groups (cancer, chronic heart failure, kyphoscoliosis, chronic obstructive pulmonary disease and interstitial lung disease) have not demonstrated additional benefit from oxygen therapy over medical air delivery. (25-30) An updated Cochrane review of chronic obstructive pulmonary disease found low quality evidence for modest relief of breathlessness. (31) The results from a large, adequately powered trial that randomised 239 participants (chronic obstructive pulmonary disease 63%, cancer 16%) to receive at least 15 hours a day of oxygen or medical air delivered via home concentrator for seven days reaffirms earlier suggestion that medical air
used in the placebo arm may not be an inert comparator as previously thought and points to the likelihood of an active intervention. (29, 32) Therefore the placebo arm of oxygen studies may provide useful preliminary data regarding the role of airflow for the relief of chronic breathlessness. This systematic review aims to identify and evaluate data from studies of airflow, both from studies of the hand-held fan and the comparator arm data for breathlessness intensity from oxygen studies, analysed as “before and after” airflow exposure cohort data.

**Aim**

To examine the current evidence for the effectiveness of airflow for the relief of chronic breathlessness.

**Methods**

The systematic review methods employed an exploratory approach in that only the airflow arm of studies were used and the data analysed as cohort “before and after” treatment.

**Study design**

The search methods employed are adapted from the Cochrane Handbook of Systematic Reviews (33) and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. (34) A review protocol is not pre-registered but available from the University of Hull Library (Flavia Swan PhD Thesis).

**Inclusion and exclusion criteria**

**Types of studies**

Randomised controlled trials, controlled clinical trials (quasi-randomised experimental trials with or without blinding) and observational cohort studies were included.
Types of participants

Adults with chronic breathlessness from any advanced disease aetiology as shown below:

- Malignancy: advanced primary and metastatic cancer patients, who have undergone disease treatments like chemotherapy, radiotherapy or surgical interventions.
- Chronic Obstructive Pulmonary Disease with forced expiratory volume in 1 second of less than 50% predicted value.
- Interstitial lung disease or pulmonary fibrosis where breathlessness is present.
- Chronic heart failure: New York Heart Association stage III-IV.
- Motor Neurone disease and other neurological disease where breathlessness is present or forced vital capacity less than 80% predicted value.
- Kyphoscoliosis: a moderate - severe sideways and forwards curvature of the spine Cobb Angle > 50° and forced expiratory volume of less than 50% predicted value.

Studies were included if at least 50% of the study population were classified as advanced, palliative or in the later stages of disease as defined above. These criteria were adapted from the Cochrane review of non-pharmacological interventions for breathlessness. (35)

Studies of participants with mild hypo or normoxaemia, who do not fore-fill the criteria for long term oxygen therapy (36) were included. Studies of hypoxic participants or patients with any condition not assessed as progressive, refractory to treatment and advanced such as asthma were excluded.

Types of exposure

Airflow: i) delivered from either a fan (hand-held or table) or non-oxygen enriched compressed air, or from a non-invasive ventilatory method (nasal cannula, mask or mouthpiece), but not nasal intermittent positive pressure ventilation and ii) directed at the cheek of the face, nasal mucosae or mouth.

Administration: as i) a single dose during ambulation, or at rest taken as needed (pro re nata),(37) ii) placebo short-burst oxygen therapy intermittent use before exercise or after
exercise for recovery (36) or iii) continuously over 15hr a day as placebo long-term oxygen therapy studies or during the night as placebo nocturnal oxygen therapy.(38)

Studies where airflow was directly administered to the trachea, or at sub-zero temperatures were excluded.

**Types of outcome measure**

**Unidimensional breathlessness outcomes**

ATS domains of dyspnea measurement (20) including breathlessness severity or intensity rated on uni-dimensional scales as shown below:

- Modified Borg Score, a categorical scale with ratio properties
- Visual Analogue Scale, 0 - 100mm anchored 0 = no shortness of breath and 100mm = shortness of breath as bad as can be
- Numerical Rating Scales, 0-10 numbered scale anchored 0 = Not breathless at all and 10 the worst imaginable breathlessness
- Likert scales with verbal responses such as “a bit better”, “much better” or “no difference” or any other validated uni-dimensional scale for measuring breathlessness.

Studies were only included if they reported the breathlessness outcome at baseline and post-treatment measured as either primary or secondary outcomes. If severity or intensity was measured as part of a multi-dimensional or composite scale, e.g. the Chronic Respiratory Questionnaire, that unidimensional measure of breathlessness was *not* extracted and analysed separately. Breathlessness related function/quality of life measures were *not* used as primary breathlessness outcomes in the absence of unidimensional scales.
Other Outcomes

Other outcomes as shown below measured as either primary or secondary outcomes.

- Participant preference and satisfaction with the treatment
- Participant withdrawal and drop-out from the studies
- Adverse effects recorded

Data sources and searches

Medline, CINAHL, AMED and Cochrane databases were searched (1985 – 2015; updated January 2018) for observational or randomised controlled trials of airflow as intervention vs control or as comparator vs oxygen. Reference lists were scanned. A full search strategy can be seen in Online Supplementary Table 1.

Study selection

Titles, abstracts (and, where unclear, full papers) were screened against the eligibility criteria by two independent reviewers FS and AN, with recourse to MJ as a third reviewer in case of disagreement.

Data extraction and synthesis

Baseline and post-intervention measures of breathlessness intensity were extracted from the fan studies and from the comparator arm of oxygen studies. Data were analysed as “before and after” airflow exposure cohort observational data.

Risk of bias

FS and AN judged the reporting quality and internal validity for each of the included studies. The cohort study was evaluated according to the Cochrane guidelines for assessing bias in a non-randomised study. As there is no tool that is applicable directly to the data extracted from the randomised controlled trials control arms, we assessed instead the quality of the parent randomised controlled trials as a proxy marker for quality data. The randomised
controlled trials were assessed with the Cochrane Risk of bias tool. (33) See online Supplementary Table 2.

**Statistical Analysis**

Results from the meta-analyses were reported for the primary outcome, breathlessness intensity or severity where heterogeneity allowed, or where not possible these were described narratively. Numerical rating scales and visual analogue scales were combined by equating one point on a numerical rating scales scale to 10mm on a visual analogue scales. (40, 41)

Data calculations for mean difference and standard deviation used STATA Version 12.1, Stata Corp LLC Texas 77845-4512, USA. Breathlessness measurements were analysed as continuous outcomes. Data from the placebo arm of cross-over randomised controlled trials were treated as single arm before-after studies. For studies that recorded median values, the mean were calculated from the extracted study data. (42) The I² statistic was used to assess heterogeneity. (43) Where the result indicated significant heterogeneity a random effects model was chosen, otherwise a fixed effects model was applied. All analyses were undertaken on Review Manager 5.5. A sensitivity analysis was attempted for any study identified as including a sub-group not fitting the review criteria of mild hypo or normoxaemia to assess for any significant difference in the breathlessness outcome between the hypoxic and non-hypoxic participants.

**Results**

A total of 403 records were identified for screening. After removal of duplicates, 78 records were reviewed. 14 abstracts were rejected for not meeting inclusion criteria; the remaining 64 full text articles were assessed for eligibility. Of these, 16 studies met the review inclusion criteria and the other 48 studies were excluded (see Figure 1; flow chart (34) and Online Supplementary Table 3, eAppendix).

Overall studies represented 929 participants (age median 61.5, range 33 to 90 years; 47% men)
Airflow was delivered by fan (13, 14, 16, 17, 44) or as medical air. (29, 32, 45-53) See Table 1 for study characteristics.
Description of fan studies

**Design:** five studies (n=230) used the fan. Two feasibility randomised controlled trials; (n =49), (13) and (n=30), (44), a feasibility cohort study (n=31), (14), a feasibility longitudinal RCT (n=70), (16) and a phase III cross-over randomised controlled trial (n=50), (17).

**Patient characteristics:** Four studies recruited a mixed population of people with breathlessness due to a variety of advanced conditions including chronic obstructive pulmonary disease (n=101), cancer (n=55), heart failure (n=23) and other causes (n=21), (13, 14, 16, 17), and one study recruited advanced cancer only (n=30). (44)

**Intervention and comparator characteristics:** three studies used the fan to face at rest (14, 17, 44), two with comparator groups; fan to leg (17), or no fan use and carer support (44), and the other was a cohort design. (14) One study assessed acceptability of the fan when used with general activity over 6 months compared with an acupressure wristband (16), and the remaining study assessed the fan when used with exercise advice over 4 weeks. (13)

**Breathlessness Outcome:** Three studies focused on the sensory-perceptual domain of dyspnea measurement and used breathlessness intensity as the primary outcome (17) or main outcome (14, 44). These studies selected the visual analogue scale (17), the numerical rating scale (44), or both visual analogue scale and numerical rating scale (14). The other two studies assessed symptom impact as well as the sensory-perceptual domain. These studies selected the numerical rating scale breathlessness intensity (13) and the Modified Borg Scale of breathlessness severity. (16)

**Other outcomes:** All of the fan studies reported participant withdrawals (13, 14, 16, 17, 44). These ranged from 0 to 6 participants. (13, 14, 44) One study reported that there were no adverse events (13) and the other fan studies did not include any adverse event details. (14, 16, 17, 44) Airflow preferences were described in four fan studies (13, 16, 17, 44) and not in one study. (14) In addition, one study quantified the experience of fan use at 2 months. (16)

Description of medical air studies
**Design:** eleven randomised controlled trials (n=699) used oxygen, helium hyperoxia or both gases for the intervention compared with medical air. (29, 32, 45-53) Study size ranged from 16 to 239 participants. (29, 48) Four were cross-over (32, 48, 49, 51) and seven used a parallel group design. (29, 45-47, 50, 52, 53) Nine studies were double blind (29, 45-52), and two were single blind. (32, 53)

**Patient characteristics:** the eleven studies represent; chronic obstructive pulmonary disease n=537, cancer n=109, other lung diseases n=21, cardiac disease n=14 and other causes n=18. Inclusion criteria required moderate to severe chronic obstructive pulmonary disease (45-50, 52, 53), advanced cancer (51), or were a mixed population with no specific stipulation of severity. (29, 32)

**Intervention Characteristics:** the source of airflow was an oxygen cylinder (32, 45-50), a sham concentrator (29), and a Douglas bag. (52) Two studies did not state the airflow source. (51, 53) Medical air or compressed air was delivered through nasal cannulae (29, 32, 45, 47, 49-51, 53), face-mask and nasal cannula (48), a non-rebreathing face-mask (46) and through a mouthpiece. (52) The flow rates varied widely in the studies; 2l/minute (29, 45), 3l/minute (47), 4l/minute (32, 49, 51), 5l/minute (53), 6l/minute (50) and 8l/minute via nasal cannula or 15l/minute with face mask. (48) Two studies did not report flow rate details. (46, 52) The timing of airflow delivery was; 15 minutes at rest (32, 51), with daily activity over 3 (50), or 6 months (45), 15 hours a day over one week (29), or in conjunction with exertion-induced breathlessness during pulmonary rehabilitation, (46, 52, 53) or a walking test. (47-49) The pulmonary rehabilitation programme parameters for airflow delivery were with treadmill exercise 3 times a week for 30 minutes over two months (53), a cycle ergometer used 3 times a week for 30 minutes over 6 weeks (46), or 3 times a week for 20 minutes over two months. (52) The 6minute walk test parameters for airflow delivery were; i) three same day 6minute walk test s with 45 minutes washout, using room air for the basal walk and compressed air for the subsequent walks (47), ii) five 6minute walk test performed over three visits, (timing not stated) using room air for the practice walk on visit one and cylinder air for the two 66minute walk test s with 60 minute washout on visits two and three (48), and iii) three same day 6minute walk test s using cylinder air with 20 minutes washout between tests at baseline, 6 and 12 weeks as well as short burst use at home with daily activity during the study period. (49)
**Breathlessness outcome:** two studies focused on the sensory-perceptual domain of dyspnea measurement and recorded breathlessness intensity as a primary outcome with the visual analogue scale and Borg scale (32) or the visual analogue scale only. (51) All of the other studies focused on symptom impact as well as the sensory-perceptual domain. (29, 45-50, 52, 53) Of these, three studies measured breathlessness intensity as a primary outcome with the numerical rating scale (29) or the Chronic Respiratory Questionnaire dyspnea domain. (45, 50) The remaining six studies identified the modified Borg scale as one of the main outcomes (47-49, 52, 53) or a secondary measure. (46) One study in addition selected the Chronic Respiratory Questionnaire. (49)

**Other outcomes:** participant withdrawals were reported in all of the studies (29, 32, 45-51, 53), apart from one. (52) Five studies reported no withdrawals (32, 46-48, 51) and in the other five studies withdrawals ranged from 2 to 21 participants. (45, 53) adverse events were poorly reported with only two studies including details; “few” or “no adverse events”. (29, 46) All of the other studies omitted reporting adverse events. (32, 45, 47-53) Airflow preferences were only reported in one study. (51) The remaining studies did not report airflow preferences (29, 32, 45-48, 50, 52, 53), although one study did quantify side-effects (29) and a second study examined preference for cylinder delivery of airflow. (50)
**Table 1 Characteristics of included studies (fan)**

<table>
<thead>
<tr>
<th>Study author</th>
<th>Study Design</th>
<th>Population (mean; standard deviation)</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Mode of gas delivery</th>
<th>Dyspnea Outcome measure(s)</th>
<th>Other Outcomes: withdrawals, Adverse Events (AE), airflow preferences</th>
<th>Timing of measurement</th>
<th>Results airflow arm only (before and after treatment) (mean; standard deviation)</th>
<th>Improvement with airflow Yes/No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Booth (2016) [14]</td>
<td>Feasibility observational cohort</td>
<td>n = 31 Males: 20 Age mean: 74.8; 11.49 Mixed population, non-malignant, cardiorespiratory disease: 8 (26%) Baseline dyspnoea score: Mean Visual analogue scale 48mm; 27.4</td>
<td>Hand-held fan to face</td>
<td>No comparator group</td>
<td>Airflow from hand-held fan to face for 5 minutes</td>
<td>Visual analogue scale (mm), numerical rating scale</td>
<td>Withdrawals = 6 AE and airflow preferences not reported</td>
<td>After 5 minutes at rest</td>
<td>Visual analogue scale = Mean 35mm; 25.7 after 5min air Mean change = 12mm; 21.2</td>
<td>Yes</td>
</tr>
<tr>
<td>Bausewein (2010) [16]</td>
<td>Feasibility longitudinal phase II randomised controlled trial</td>
<td>n = 70 Males: 36 Age mean: 65.6yrs SD 8.80 chronic obstructive pulmonary disease = 45, cancer = 25 Baseline dyspnoea score: 3.7; 1.83</td>
<td>Hand-held fan to face</td>
<td>Wristband</td>
<td>Airflow from hand-held fan</td>
<td>Modified Borg score</td>
<td>Withdrawals at 2 months =16/33 (48%) AE not reported Airflow preferences: Positive = 13/38 Negative = 7/38</td>
<td>Monthly over 6 months</td>
<td>Mean Borg score change over 2 months = 0.8; 2.1, p = 0.90</td>
<td>No, phase II not powered to test</td>
</tr>
<tr>
<td>Galbraith (2010) [17]</td>
<td>Cross-over randomised controlled trial</td>
<td>n = 50 Males: 23 Age mean: 71.3, range 33-90yrs Mixed population; chronic obstructive pulmonary disease = 26, lung cancer = 11, heart disease = 15 Baseline dyspnoea score:</td>
<td>Hand-held fan to face</td>
<td>Hand-held fan to leg</td>
<td>Airflow from hand-held fan to face for 5 minutes</td>
<td>Visual analogue scale (mm)</td>
<td>Withdrawals = 1 AE not reported Airflow preferences: positive patient comments, numbers not reported</td>
<td>After 5 minutes at rest and after 10 minute washout</td>
<td>Visual analogue scale = -7.0mm Median change after 5 minutes Fan/face 1st group (interquartile range 1.5 - 14.5) Visual analogue scale = -10.0mm Median change incl 10 minute washout Fan/face 1st group</td>
<td>Yes</td>
</tr>
<tr>
<td>Study</td>
<td>Study design</td>
<td>n</td>
<td>Description</td>
<td>Group 1: Hand-held fan</td>
<td>Group 2: Table fan</td>
<td>Withdrawals</td>
<td>Adverse events</td>
<td>Airflow preference</td>
<td>After 4 weeks</td>
<td>After 5 minutes at rest</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------------------</td>
<td>-----</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>-------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Wong (2017) [44]</td>
<td>Feasibility phase II randomised controlled trial</td>
<td>30</td>
<td>Males: 14. Age: not reported. Lung cancer = 13, other cancers = 17. Baseline dyspnoea score mean = 5.6; 1.55.</td>
<td>Table fan with low flow rate. Placebo accompanied by carer. Airflow from table fan to face for 5 minutes.</td>
<td>Airflow from table fan to face for 5 minutes.</td>
<td>No withdrawals. Adverse events not reported. Airflow preference: mixed patient comments, numbers not reported.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study author</td>
<td>Study Design</td>
<td>Population (mean; standard deviation)</td>
<td>Intervention</td>
<td>Comparator</td>
<td>Mode of gas delivery</td>
<td>Dyspnea Outcome measure(s)</td>
<td>Other Outcomes: withdrawals, AE, airflow preferences</td>
<td>Timing of measurement</td>
<td>Results airflow arm only (before and after treatment) (mean; standard deviation)</td>
<td>Improvement with airflow Yes/No</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------</td>
<td>---------------------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>----------------------</td>
<td>---------------------------</td>
<td>-------------------------------------------------</td>
<td>----------------------</td>
<td>-----------------------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
</tbody>
</table>
| Abernethy (2010) [29] | Double-blind randomised controlled trial | n = 239 Males: 63%  
Age mean: Air = 74yrs; 10  
Mixed: chronic obstructive pulmonary disease = 152,  
Primary lung cancer = 33  
Baseline dyspnoea score: Am air = 4.6; 2.4  
Pm air = 4.7; 2.3 | Oxygen | Room air via concentrator | 2l/min via nasal cannula for at least 15hrs a day (long term oxygen therapy) | numerical rating scale 1-10 | Withdrawals = 15  
Few adverse events, number not reported  
Side-effects reported  
Airflow preferences not reported, oxygen only | Am and pm each day, within 30 minutes of waking and bedtime for 7 days | Am = -0.7 numerical rating scale point change  
Pm = -0.5 numerical rating scale point change, (p = 0.5) | Yes |
Age Median: 71 Range: 54-90yrs  
Lung Cancer 20, chronic obstructive pulmonary disease 13, Cardiac 4  
Baseline dyspnoea score: Visual analogue scale 59mm | Oxygen | Cylinder air | 4l/minute for 15 minutes via nasal cannula | Visual analogue scale (mm) Modified Borg Scale | No withdrawals  
Adverse events and airflow preferences not reported | After 15 minutes of breathing oxygen or air at rest. | Visual analogue scale = -11mm change after air  
48mm, p<0.001 | Yes |
<p>| Study | Design | Participants | Symptoms | Baseline | Intervention | CRQ | Withdrawals | Adverse Events | Flow Preferences | Flow Preferences | Flow Preferences | Flow Preferences | Outcome |
|-------|--------|--------------|----------|----------|--------------|-----|-------------|--------------|----------------|----------------|----------------|----------------|-------------|---------|
| Eaton (2006) [45] | Double-blind parallel randomised controlled trial | n = 78 Males: 36 | Moderate/severe chronic obstructive pulmonary disease | Air = 17.5; 4.2 | Oxygen Cylinder air 2l/minute via nasal cannula over 6 months (SBOT) | CRQ Withdrawals = 21 | No | Adverse events and airflow preferences not reported | Monthly over 6 months | Chronic respiratory questionnaire = Average change over 6 months: air group = -3.6 | No |
| Eves (2009) [46] | Double-blind randomised controlled trial | n = 38 Males: 23 | Stable chronic obstructive pulmonary disease | Constant load exercise Borg mean: Air = 6.0; 2.2 Incremental load exercise Borg mean: Air = 5.6; 2.0 | Helium-hyperoxia (60% HE: 40% O²) Cylinder air Face mask (non-rebreathing) | Modified Borg score | No withdrawals | No Adverse events | Airflow preferences not reported | During exercise test before and after 6 weeks pulmonary rehabilitation programme, 3 times a week for 30 minutes on cycle ergometer | Constant load exercise Borg mean: Air = 4.2; 2.1 mean change = -1.8 (95% CI -3.1 to -0.2), p &lt; 0.05 Incremental load exercise Borg mean: Air = 5.6; 2.1 No change (95% CI -0.7 to 0.7) | Yes |
| Jolly (2001) [47] | Double-blind randomised controlled trial | n = 20 Males: 19 | Stable chronic obstructive pulmonary disease | Borg mean score: Desat group Baseline 6minute walk test = 5.82 (SEM 0.46) Non-desat group Baseline 6minute walk test = 4.22 (SEM 0.46) | Oxygen Cylinder air 3l/minute via nasal cannula | Modified Borg score | No withdrawals | Adverse events and airflow preferences not reported | Before and after 3 x 6 MWTs with at least 45minutes washout between walks | Borg mean score: Desat group Air 6minute walk test = 5.82 (SEM 0.42) No change Non-desat group Air 6minute walk test = 4.44 (SEM 0.73) No change | No |</p>
<table>
<thead>
<tr>
<th>Reference</th>
<th>Study Design</th>
<th>n</th>
<th>Gender</th>
<th>Age Median</th>
<th>Disease Description</th>
<th>Baseline Dyspnoea Score</th>
<th>6MWT Baseline Score</th>
<th>6MWT Oxygen Use</th>
<th>6MWT Helium Use</th>
<th>Modified Borg Score</th>
<th>Withdrawals</th>
<th>Adverse Events</th>
<th>Airflow Preferences</th>
<th>Washout</th>
<th>Before and After 6MWT Test</th>
<th>Borg Mean Score</th>
<th>Change</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marciniuk (2007)</td>
<td>Double-blind crossover randomised controlled trial</td>
<td>n = 16 Males: 7</td>
<td>Age mean: 67 (SD 8)</td>
<td>Moderate to severe chronic obstructive pulmonary disease</td>
<td>Borg mean score Baseline 6MWT = 5; 2</td>
<td>100% Oxygen or Helium-hyperoxia (70% HE: 30% O²)</td>
<td>Cylinder air</td>
<td>15l/minute via face mask</td>
<td>8l/minute via nasal cannula</td>
<td>Modified Borg score</td>
<td>No withdrawals</td>
<td>Adverse events and airflow preferences not reported</td>
<td>Before and after each 6 MWTs on visit 1.2 and 3 with 60 minutes washout between walks</td>
<td>Borg mean score After 6MWT Air = 3.5</td>
<td>mean Borg score change = -1.5 decrease</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McDonald (1995)</td>
<td>Double-blind crossover randomised controlled trial</td>
<td>n = 26 Males: 24</td>
<td>Age mean: 73; 6</td>
<td>Stable severe chronic obstructive pulmonary disease</td>
<td>6MWT Baseline Oxygen = 3.8; 1.4</td>
<td>Chronic respiratory questionnaire = 14; 5</td>
<td>Oxygen</td>
<td>Cylinder air</td>
<td>4l/minute via nasal cannula</td>
<td>Modified Borg score chronic respiratory questionnaire</td>
<td>Withdrawals = 7</td>
<td>Adverse events and airflow preferences not reported</td>
<td>After 6 and 12 weeks of home cylinder air using 6MWT exercise test with 20 minute washout between walks</td>
<td>Borg Mean score Home air: 6minute walk test with cylinder air = 3.8 (SD 1.5) No change chronic respiratory questionnaire score Home = 17; 6</td>
<td>3 point change</td>
<td>No with 6minute walk test</td>
<td>Yes with chronic respiratory questionnaire</td>
<td></td>
</tr>
<tr>
<td>Moore (2011)</td>
<td>Double-blind randomised controlled trial</td>
<td>n = 143 Males: 99</td>
<td>Age mean: 71.8yrs; 9.8</td>
<td>Stable chronic obstructive pulmonary disease</td>
<td>Baseline dyspnoea score: Air = 17.5; 4.9</td>
<td>Oxygen</td>
<td>Cylinder air</td>
<td>6l/minute via nasal cannula at home for 12 weeks with activity (SBOT)</td>
<td>Chronic respiratory questionnaire</td>
<td>Withdrawals = 4</td>
<td>Adverse events not reported</td>
<td>Airflow preferences 45% prefer no cylinder</td>
<td>At 4 weeks and 12 weeks</td>
<td>Air: 4 weeks = 18.4; 5.8</td>
<td>12 weeks = 18.4; 5.8</td>
<td>Air: chronic respiratory questionnaire = Mean change at 4 and 12 weeks = 0.9</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Philip (2006)</td>
<td>Double-blind cross-over randomised controlled trial</td>
<td>n = 51 Males: 31</td>
<td>Age median: 65</td>
<td>Range: 33-82yrs</td>
<td>Non small cell lung cancer = 22, Small cell lung cancer = 6, Breast = 8, Colorectal = 4 Others = 11</td>
<td>Oxygen</td>
<td>Medical Air</td>
<td>4l/minute for 15 minutes via nasal cannula</td>
<td>Visual analogue scale (mm)</td>
<td>No withdrawals</td>
<td>Adverse events not reported</td>
<td>Airflow preferences: Positive: n=15 (29%)</td>
<td>Before and after 15 minutes of gas</td>
<td>Visual analogue scale median After air 1st = -3mm change (range -19 to 7)</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>n</td>
<td>Age</td>
<td>Disease Type</td>
<td>Baseline Dyspnoea Score: Before Training</td>
<td>Borg Score Before Training</td>
<td>Borg Score After Training</td>
<td>Borg Change</td>
<td>Withdrawals</td>
<td>Adverse Events</td>
<td>Gender</td>
<td>Study Duration</td>
<td>Exercise Protocol</td>
<td>Follow-up</td>
<td>Withdrawals</td>
<td>Adverse Events</td>
<td>Patient Preferences</td>
<td>Borg Change</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-------------------------------</td>
<td>-------</td>
<td>-----</td>
<td>--------------------------------</td>
<td>------------------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------</td>
<td>--------------</td>
<td>-------------</td>
<td>----------------</td>
<td>--------</td>
<td>----------------</td>
<td>-------------------</td>
<td>-----------</td>
<td>-------------</td>
<td>------------------</td>
<td>-------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Scorsone (2010) [52]</td>
<td>Double-blind randomised controlled trial</td>
<td>30</td>
<td>67.3</td>
<td>Moderate to severe obstructive pulmonary disease</td>
<td>Visual analogue scale median Air 1st: 52mm (range 23-92)</td>
<td>Air 1st: 52mm (range 23-92)</td>
<td>Air 2nd: 42mm (range 10-70)</td>
<td>Air 2nd: -11.5mm change (range -20 to 45)</td>
<td>No withdrawals</td>
<td>Adverse events and airflow preferences not reported</td>
<td>Male: 23</td>
<td>6 months</td>
<td>20 mins cycle ergometer</td>
<td>3 months</td>
<td>2</td>
<td>Male: 23</td>
<td>Male: 23</td>
<td>Male: 23</td>
</tr>
<tr>
<td>Wadell (2001) [53]</td>
<td>Single-blind crossover randomised controlled trial</td>
<td>20</td>
<td>67</td>
<td>Stable obstructive pulmonary disease</td>
<td>Visual analogue scale median Air 1st: 52mm (range 23-92)</td>
<td>Air 1st: 52mm (range 23-92)</td>
<td>Air 2nd: 42mm (range 10-70)</td>
<td>Air 2nd: -11.5mm change (range -20 to 45)</td>
<td>No withdrawals</td>
<td>Adverse events and airflow preferences not reported</td>
<td>Male: 10</td>
<td>6 months</td>
<td>30 mins treadmill</td>
<td>3 months</td>
<td>2</td>
<td>Male: 10</td>
<td>Male: 10</td>
<td>Male: 10</td>
</tr>
</tbody>
</table>
Risk of Bias

The quality appraisal is summarised in Online Supplementary Table 2 and described below.

Allocation: all of the studies, apart from one, a cohort design (14), were described as randomised controlled trials. It was possible to verify the randomisation process in eight studies. (13, 16, 17, 29, 32, 45, 46, 50). There was insufficient information to determine the risk of allocation bias in the other randomised controlled trials. (44, 47-49, 51-53)

Blinding: two of the fan studies attempted to blind the participants (16, 17); a placebo wristband was used as a comparator (16) and participants were not told if the fan to face or fan to leg was the active intervention. (17) There was no blinding in two studies, a cohort and phase II randomised controlled trial (13, 14), and the fifth study stated single blinding that could not be verified from the methods described. (44) All five were judged high risk of bias due to incomplete blinding or limited description. Nine medical air randomised controlled trials were described as double blind. (29, 45-52) All were judged low risk of bias (29, 45, 46, 48-50, 52), apart from one study that was unclear due to the lack of detail reported. (51) Two randomised controlled trials were single blind (32, 53); one was judged low risk of bias (32) and the other was regarded as unclear risk due to the inadequate description. (53)

Incomplete outcome data: 13 studies adequately addressed withdrawals and incomplete outcome data; these were considered low risk of bias.(13, 14, 17, 29, 32, 46-53) Three studies were uncertain risk (16, 45); one due to the proportion of attrition (16) and the other two lacked description of how any missing data were statistically managed. (44, 45)

Selective Outcome reporting: all of the studies reported the pre-specified outcomes and were judged as low risk of bias. (13, 14, 16, 17, 29, 32, 44-53) Study protocols were available for eight studies. (13, 14, 16, 17, 29, 46, 50, 51)

Other issues of bias: twelve studies appeared free from other bias and were judged low risk. (13, 16, 17, 29, 44-46, 48, 50-53) Three studies reported insufficient information to adequately assess risk (32, 47, 49), and one study, a cohort design was judged high risk. (14)
**Effect of interventions**

The airflow was delivered, i) at rest (14, 17, 32, 44, 51) ii) over days or weeks (either intermittently or as periods of continuous flow) whilst the participant continued with usual general activities (13, 16, 29, 45, 50) or iii) during specific episodes of exertion induced breathlessness. (46-49, 52, 53)

i) At rest

Five studies demonstrated improvement with airflow delivery at rest.

Results from 5 minutes fan use to the face in three studies were visual analogue scale breathlessness intensity difference from baseline mean -7mm (CI -11.5 to -2.5) (17), and mean -12mm (CI -19.3 to -4.4) (14), and for the numerical rating scale mean change -1.53 (-9.6 to -6.5). (44)

Cylinder medical air delivery for 15 minutes demonstrated improvement visual analogue scale breathlessness intensity mean -11mm (CI -17.0 to -5.0) (32), and mean -13mm (CI -20.5 to -6.3). (51) Four studies were sub-divided into two groups and included in meta-analyses.

*Fan*

Airflow from the fan at rest improved breathlessness in a mixed population (n=111; 58% cancer) visual analogue scale (mm) mean difference, -11.17 (confidence intervals -16.60 to -5.74), p=0.06. Significant heterogeneity was observed, Chi² p-value = 0.2, ($I^2 = 64\%$) (See Figure 2).

<<insert Figure 2 Meta-analysis of fan at rest >>

*Medical air*

Airflow delivered as cylinder medical air at rest improved breathlessness in advanced cancer (n=89) visual analogue scale (mm) mean difference -12.0, (confidence intervals -16.6 to -7.4), P<0.0001. No evidence of heterogeneity was observed, Chi² P value = 0.6, ($I^2 =0\%$).
ii) General activity

Six studies used airflow at home with everyday general activity. A narrative description was used for these due to study diversity. Breathlessness points change from four cylinder air studies were mixed (29, 45, 49, 50), with Chronic Respiratory Questionnaire -3.6 after 6 months (45), 3.0 after 12 weeks (49), or 0.9 at 12 weeks (50), or numerical rating scale -0.7 (am) and -0.5 numerical rating scale (pm) after 7 days. (29) In the two fan studies a modified Borg score of -0.6 (SD 2.1) was found after 2 months (16), but there was no numerical rating scale score change after 4 weeks of fan use with exercise advice. (13)

iii) Exertion-induced breathlessness

Six studies examined airflow delivery with exertion-induced breathlessness. Results for mean Borg breathlessness score during a walking test for three studies varied; no change during a 6minute walk test repeated on the same day (47), or at 12 weeks (49), and improvement -1.5 for a 6 minute walk test repeated on 3 separate visits. (48) Airflow delivered during a constant load exercise test after PR in three studies also demonstrated variable improvement in mean Borg breathlessness scores; -1.8 points (46), and -3 point (52) using a cycle ergometer, and -0.5 point from a treadmill test. (53) Two studies were suitable to include in a meta-analysis (See Figure 4). (46, 52)

Medical air

Airflow delivered as cylinder medical air during a constant load exercise test after PR in chronic obstructive pulmonary disease (n=29) significantly improved breathlessness Borg score mean difference -2.9, (CI -3.2 to -2.7), p<0.0001. No evidence of heterogeneity was observed, Chi² p-value = 0.7, (I² =0%), (Figure 4).
Discussion

These exploratory data support that facial and nasal airflow delivery at rest offers relief of breathlessness intensity consistent with a moderate clinically important difference, (54, 55) and during exertion. (46, 52) All participants in the cylinder medical air delivery at rest studies had advanced cancer, but nearly half of those in the fan “at rest” studies had other conditions indicating that airflow for breathlessness at rest is of benefit irrespective of cause.

In a recent pooled qualitative data study of facial airflow use from the fan in 133 people with chronic breathlessness (56), over 80% patients reported some or substantial benefit.(57) However, the data presented here varied with regard to relief of breathlessness intensity when facial or nasal airflow delivery was used with everyday general activity or with exertion induced breathlessness. This may reflect the use of outcome measures that do not reliably capture change in breathlessness intensity in the context of exertion. Studies that used a 6 minute walk test (47-49) highlight the problem of a self-paced test that allows patients to control their walking speed and thus limit the maximal level of exertion–induced breathlessness experienced. In contrast, studies that used an externally paced test, such as the cycle ergometer, identified relief of breathlessness intensity. (46, 52) The relationship between exercise and breathlessness intensity is complex, and measuring one without taking the other into account may miss relevant improvement. Scores are likely to remain static after the introduction of an intervention as patients are able to exert themselves to the same level of breathlessness without noticing an increase in their exercise tolerance (58), or indeed the outcome may be of little value to the patient. (57)

A previous study of recovery time after an incremental shuttle walk test in people with thoracic cancer (n=57) reported a rapid reduction in breathlessness intensity with a return to baseline time of median 4 (interquartile range 2-5) minutes. (59) The analysis of 133 patient interviews found that a faster recovery time was a key patient-reported benefit of airflow delivered from the fan, irrespective of breathlessness intensity. (57) Even though recovery time may only be a matter of minutes, interventions which shorten this further are clearly welcomed and give the patient a sense of self-control that may help prevent a breathlessness-anxiety spiral. The ability to recover quickly and predictably from bouts of exertion is likely to encourage further activity and prevent the deconditioning cycle.
The fan therefore seems suitable as a patient-delivered intervention to target the recovery time from exertion-induced breathlessness. Preliminary magnetoencephalography imaging data suggests airflow delivery during recovery from exercise may modulate central perception of breathlessness by modifying sensory attention. (60) Cooling of the facial skin innervated by the 2nd and 3rd branches of the trigeminal nerve and/or stimulation of nasal mucosa and upper airway ‘flow’ receptors are reported to improve breathlessness intensity and exercise tolerance (18, 19, 61, 62) and could “fool” the brain into thinking that the respiratory status is adequate. (22)

Unpleasant respiratory sensations associated with exercise are known to adversely influence adherence to an exercise regime. (63) Therefore, use of airflow as part of pulmonary rehabilitation may help the problems of low patient attendance and poor maintenance of long term outcomes. (64-67) Facial airflow from fan use during a cycle ergometer test in chronic obstructive pulmonary disease patients resulted in significant breathlessness reduction and a longer total exercise time. (68) Likewise, the meta-analysis result from this systematic review suggest significant relief of breathlessness when airflow is delivered during exercise. These data highlight the potential value of using airflow delivery with pulmonary rehabilitation or home based exercise programmes. In addition, intervention preference and adverse event data support the role of the fan in this context as a portable device that is unlikely to harm and therefore appropriate for the majority of patients to try.

Finally, it is likely that any positive benefits of airflow delivery from fan use with everyday general activity and at rest were not captured in the review data. The lack of signal from the results may in part reflect the complexity and the nuances of when, where and how this intervention is used by patients. (57) Current breathlessness management is modelled on a complex intervention, of which the fan is identified as a valuable therapeutic component alongside other interventions and strategies that are tailored to the patient’s breathlessness needs. (11, 69)

**Limitation of methods**

Data were analysed as cohort “before and after” design, and no adjustments were made to control for confounding bias. The pre-post comparison increases the potential risk of bias and it is possible that results may be influenced by the timing of “before and after” measures. For
example, studies of longer duration (up to 6 months) may not be representative of the immediate benefits of airflow, but rather reflect more complex use and mechanism of any observed benefit may be related to reconditioning, facilitated by airflow, over time. Risk of bias was assessed using a tool designed for randomised controlled trials therefore it is possible that this assessment may not capture potential sources of bias associated with the observational methods used in this systematic review.

Overall, the qualitative synthesis represents findings from 929 participants the largest to date, however the meta-analyses pertain to a small number of participants and only provide a preliminary indication of the pooled effect estimate of airflow. The meta-analyses involve few studies therefore heterogeneity is difficult to estimate and the accuracy of the \( I^2 \) value is less certain. (70) The number of studies that fulfilled the review criteria was restricted by the need for baseline breathlessness measures. Some of the included studies (32, 51) did not report repeated measurements in a format suitable for meta-analysis necessitating statistical assumptions. (42)

**Implications for practice and further research**

Airflow is safe and should be used as an adjunct to treatment for breathlessness at rest in those who do not require oxygen-enriched air. Clinicians should consider airflow an important intervention to use as part of a breathlessness management programme in breathlessness at rest irrespective of cause. The relief of breathlessness during exertion in those with chronic obstructive pulmonary disease may provide a useful intervention during pulmonary rehabilitation where breathlessness is a reason for poor adherence.

The fan, when taught by an appropriately trained clinician, offers patients an inexpensive and portable source of airflow likely to benefit exertion-induced breathlessness. Recovery time from exertion induced breathlessness is an important patient-reported outcome and further work is needed to explore the role of airflow in recovery, self-efficacy and increased daily activity as part of complex breathlessness intervention programmes including rehabilitation.
Conclusion

These data support facial or nasal airflow for clinically meaningful relief of breathlessness at rest. This systematic review pulls together the growing evidence to support airflow as an effective self-management option for people with chronic breathlessness and identifies airflow as an intervention for future study.

Declarations.

**Authorship**: Concept - FS; Design - FS, MJJ, CB, SB, JY; Data collection - FS, AN; Data analysis - FS, VA, MB; Data interpretation- All; Draft manuscript FS; critical revision of manuscript for intellectual content – All; approval final manuscript – All.

**Funding**: This study was funded as part of a University of Hull PhD studentship (Flavia Swan)

**Declaration of conflicts of interest**: The Authors declare that there is no conflict of interest.

**Data management and sharing**: The full search strategy is found in the Online Supplementary materials and included and excluded papers are presented.
References


49. McDonald CF, Blyth CM, Lazarus MD, Marschner I, Barter CE. Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia. American Journal of Respiratory and Critical Care Medicine [Internet]. 1995; (5 Pt 1):[1616-9 pp.]


